July 1, 2013
Breast Cancer Patients Need Nuvilex
The past 2 weeks have been a mixed bag for those following breast cancer treatments and funding. As a result, it seems apparent that the space could use some good development news. While new product development isn’t around the corner for Nuvilex, Inc. (OTCQB – NVLX - $0.105 – Spec Buy), the Company’s positioning and prospects in its breast cancer therapy studies remain outstanding. Moreover, as further research studies are conducted, it is likely that the Firm’s live-cell encapsulation therapy will become a high profile proposition.
Each year, over 200,000 women in the U.S are diagnosed with breast cancer and over 40,000 deaths are caused by the disease. These large numbers, combined with the high rate of survivability and organizations founded to fight the disease and support current patients have arguably made breast cancer the highest profile of all cancers. Therefore, it is troubling that some of the biggest stories in breast cancer of late have nothing to do with treatment development success.
Instead, breast cancer patients have been treated with word that Hollywood starlet Angelina Jolie recently underwent a double mastectomy as a preventive measure, prompting many at-risk women to consider the same procedure. While Ms. Jolie’s admission is noble and admirable, the American Cancer Society has urged caution against such surgeries, especially given that the risk of developing cancer may not be eliminated.
Separately, it has come to light that the executive director of the Susan G. Komen Foundation, which is the ubiquitous non-profit sponsor of events to raise funds in order to fight breast cancer, has earned a very high salary despite substantial declines in fundraising, which has given the organization a black eye. These unusual stories unfortunately divert attention away from very promising therapies such as the one being developed by Nuvilex. Clearly, those patients potentially at risk for the disease would prefer that new treatment options under development be at the forefront of the space rather than soap opera-type of news stories.
Nuvilex affiliate SG Austria conducted Phase I/II clinical trials in dogs with spontaneously occurring mammary tumors; this animal model is closely related to the development of breast cancer in humans. Results of the study were remarkably similar to its well-known human Phase II pancreatic cancer trial. For example, greater degrees of tumor shrinkage were observed in those dogs treated with encapsulated pro-drug-activating cells as well as the pro-drug cyclophosphamide versus those receiving cyclophosphamide alone. In the case where two spontaneous mammary tumors grew in the same animal, one tumor was treated with cyclophosphamide alone and the other was treated with the encapsulated cell/cyclophosphamide combination. The combination treatment resulted in 70% tumor shrinkage as compared to the 20% shrinkage seen with the drug alone.
It is evident that the results of this animal trial could lead to a future human breast cancer clinical trial using the Company’s live-cell encapsulation platform, which should be viewed as a major development given the different approach engaged by Nuvilex, along with its results, as compared with current therapies. The bottom line is that the Company’s 2 trials clearly illustrate the great potential efficacy in using encapsulated cells with a pro-drug as a targeting device for the treatment of solid pancreatic and mammary tumors, which will substantially raise Nuvilex’s profile and valuation.
You Might Also Like
Senior Analyst: Robert Goldman
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.